Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
57 studies found for:    "Schwannoma"
Show Display Options
Rank Status Study
21 Recruiting 18F-DOPA-PET in Planning Surgery in Patients With Gliomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Meningioma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Tumor;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Meningeal Hemangiopericytoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Subependymal Giant Cell Astrocytoma;   Adult Subependymoma;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Ependymoblastoma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebellar Astrocytoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Medulloepithelioma;   Childhood Mixed Glioma;   Childhood Supratentorial Ependymoma;   Meningeal Melanocytoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Adult Brain Tumor;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pilomyxoid Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligoastrocytoma;   Untreated Childhood Anaplastic Oligodendroglioma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Diffuse Astrocytoma;   Untreated Childhood Fibrillary Astrocytoma;   Untreated Childhood Gemistocytic Astrocytoma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliomatosis Cerebri;   Untreated Childhood Gliosarcoma;   Untreated Childhood Medulloblastoma;   Untreated Childhood Oligoastrocytoma;   Untreated Childhood Oligodendroglioma;   Untreated Childhood Pilocytic Astrocytoma;   Untreated Childhood Pilomyxoid Astrocytoma;   Untreated Childhood Pineoblastoma;   Untreated Childhood Pleomorphic Xanthoastrocytoma;   Untreated Childhood Protoplasmic Astrocytoma;   Untreated Childhood Subependymal Giant Cell Astrocytoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor;   Untreated Childhood Visual Pathway and Hypothalamic Glioma;   Untreated Childhood Visual Pathway Glioma
Interventions: Drug: fluorine F 18 fluorodopa;   Procedure: positron emission tomography;   Procedure: computed tomography;   Procedure: diffusion-weighted magnetic resonance imaging;   Procedure: perfusion-weighted magnetic resonance imaging;   Procedure: therapeutic conventional surgery;   Procedure: biopsy;   Other: laboratory biomarker analysis
22 Active, not recruiting RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Conditions: Acoustic Schwannoma;   Adult Anaplastic (Malignant) Meningioma;   Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Brain Stem Glioma;   Adult Choroid Plexus Neoplasm;   Adult Craniopharyngioma;   Adult Diffuse Astrocytoma;   Adult Ependymoblastoma;   Adult Ependymoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Medulloblastoma;   Adult Mixed Glioma;   Adult Myxopapillary Ependymoma;   Adult Oligodendroglioma;   Adult Papillary Meningioma;   Adult Pilocytic Astrocytoma;   Adult Pineal Gland Astrocytoma;   Adult Pineoblastoma;   Adult Pineocytoma;   Adult Primary Melanocytic Lesion of Meninges;   Adult Subependymal Giant Cell Astrocytoma;   Adult Subependymoma;   Adult Supratentorial Primitive Neuroectodermal Tumor;   Malignant Adult Intracranial Hemangiopericytoma
Interventions: Drug: Gamma-Secretase Inhibitor RO4929097;   Procedure: Therapeutic Conventional Surgery;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Temozolomide;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
23 Active, not recruiting Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
24 Completed
Has Results
Recovery of Visual Acuity in People With Vestibular Deficits
Conditions: Vestibular Neuronitis;   Vestibular Neuronitis, Bilateral;   Vestibular Schwannoma
Interventions: Other: Control exercises;   Other: gaze stabilization exercises
25 Unknown  A Study of Nilotinib in Growing Vestibular Schwannomas
Conditions: Volumetric Tumor Response and Lack of Tumor Progression;   Quality of Life of Patients on Nilotinib Versus Not
Intervention: Drug: Nilotinib
26 Unknown  Hippocampal Radiation Exposure and Memory
Conditions: Arteriovenous Malformation;   Schwannoma;   Trigeminal Neuralgia
Intervention:
27 Active, not recruiting Stereotactic Body Radiotherapy for Spine Tumors
Conditions: Spinal Metastases;   Vertebral Metastases;   Benign Spinal Tumors;   Chordoma;   Meningioma;   Schwannoma;   Neurofibroma;   Paragangliomas;   Arteriovenous Malformations
Intervention: Radiation: stereotactic body radiotherapy
28 Recruiting Cyberknife Radiosurgery for Patients With Neurinomas
Conditions: Sporadic Acoustic Neuromas;   Useful Hearing
Intervention: Radiation: Radiosurgery
29 Active, not recruiting Natural History Study of Patients With Neurofibromatosis Type 2
Conditions: Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
Intervention:
30 Active, not recruiting Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Conditions: Neoplasms;   Nervous System Disease;   Vestibular Disease
Intervention:
31 Unknown  Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
32 Recruiting Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis
Conditions: Whole Body Imaging;   Magnetic Resonance Imaging;   Neurofibromatosis 1;   Diffusion Magnetic Resonance Imaging;   Peripheral Nerve Sheath Tumors, Malignant
Intervention: Other: Additional imaging or surgery
33 Active, not recruiting Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Conditions: Neurofibromatosis Type 1;   Sarcoma
Interventions: Biological: filgrastim;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Procedure: conventional surgery;   Radiation: radiation therapy
34 Recruiting Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Conditions: Malignant Peripheral Nerve Sheath Tumors;   MPNST;   Sarcoma
Interventions: Drug: everolimus;   Drug: bevacizumab
35 Terminated Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Condition: Malignant Peripheral Nerve Sheath Tumors
Intervention: Drug: imatinib mesylate
36 Active, not recruiting Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Hemangiopericytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Synovial Sarcoma;   Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Drug: ifosfamide
37 Active, not recruiting Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Myxoid Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Mesenchymoma;   Adult Malignant Peripheral Nerve Sheath Tumor;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Adult Unclassified Pleomorphic Sarcoma of Bone;   Childhood Anaplastic Rhabdomyosarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Malignant Peripheral Nerve Sheath Tumor;   Childhood Mixed Alveolar Rhabdomyosarcoma;   Childhood Synovial Sarcoma;   Dermatofibrosarcoma Protuberans;   Malignant Adult Hemangiopericytoma;   Malignant Childhood Hemangiopericytoma;   Metastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Untreated Childhood Rhabdomyosarcoma
Interventions: Biological: Cixutumumab;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
38 Completed Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Conditions: Sarcoma;   Synovial Sarcoma;   Leiomyosarcoma;   Malignant Peripheral Nerve Sheath Tumor
Intervention: Drug: Sorafenib and Dacarbazine
39 Recruiting Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
Conditions: Neurofibromatosis;   MPNST
Interventions: Procedure: MRI, FDG-PET/CT scans;   Procedure: [18F]-FLT-PET/CT scans
40 Active, not recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft Part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Myxoid Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Mesenchymoma;   Adult Malignant Peripheral Nerve Sheath Tumor;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Adult Unclassified Pleomorphic Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Corpus Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma;   Unclassified Pleomorphic Sarcoma of Bone
Interventions: Drug: Vismodegib;   Drug: Gamma-Secretase Inhibitor RO4929097;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-57) Show next page of results    Last Page
Indicates status has not been verified in more than two years